NEOS Investment Management LLC Buys New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

NEOS Investment Management LLC purchased a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,672 shares of the specialty pharmaceutical company’s stock, valued at approximately $206,000.

Other institutional investors have also modified their holdings of the company. Townsquare Capital LLC acquired a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $220,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Jazz Pharmaceuticals by 17.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,899 shares of the specialty pharmaceutical company’s stock worth $1,326,000 after buying an additional 1,729 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after buying an additional 100,112 shares during the period. Martingale Asset Management L P increased its stake in shares of Jazz Pharmaceuticals by 190.2% during the 3rd quarter. Martingale Asset Management L P now owns 5,569 shares of the specialty pharmaceutical company’s stock valued at $620,000 after acquiring an additional 3,650 shares during the last quarter. Finally, Captrust Financial Advisors boosted its position in shares of Jazz Pharmaceuticals by 9.5% in the third quarter. Captrust Financial Advisors now owns 4,965 shares of the specialty pharmaceutical company’s stock worth $553,000 after acquiring an additional 430 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the topic of a number of recent analyst reports. Barclays reaffirmed an “overweight” rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Royal Bank of Canada cut their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Piper Sandler reiterated an “overweight” rating and set a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Finally, Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their price target for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $187.71.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at $4,826,778.66. This represents a 10.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,736 shares of company stock valued at $4,022,825. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $124.15 on Tuesday. The firm has a 50-day moving average of $132.36 and a two-hundred day moving average of $122.78. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $7.54 billion, a P/E ratio of 17.49, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.